Kinins and kinin receptors in the nervous system.
Kinins, including bradykinin and kallidin, are peptides that are produced and act at the site of tissue injury or inflammation. They induce a variety of effects via the activation of specific B1 or B2 receptors that are coupled to a number of biochemical transduction mechanisms. In the periphery the actions of kinins include vasodilatation, increased vascular permeability and the stimulation of immune cells and peptide-containing sensory neurones to induce pain and a number of neuropeptide-induced reflexes. Mechanisms for kinin synthesis are also present in the CNS where kinins are likely to initiate a similar cascade of events, including an increase in blood flow and plasma leakage. Kinins are potent stimulators of neural and neuroglial tissues to induce the synthesis and release of other pro-inflammatory mediators such as prostanoids and cytotoxins (cytokines, free radicals, nitric oxide). These events lead to neural tissue damage as well as long lasting disturbances in blood-brain barrier function. Animal models for CNS trauma and ischaemia show that increases in kinin activity can be reversed either by kinin receptor antagonists or by the inhibition of kinin production. A number of other central actions have been attributed to kinins including an effect on pain signalling, both within the brain (which may be related to vascular headache) and within the spinal dorsal horn where primary afferent nociceptors can be stimulated. Kinins also appear to play a role in cardiovascular regulation especially during chronic spontaneous hypertension. Presently, however, direct evidence is lacking for the release of kinins in pathophysiological conditions of the CNS and it is not known whether spinal or central neurones, other than afferent nerve terminals, are sensitive to kinins. A more detailed examination of the effects of kinins and their central pharmacology is necessary. It is also important to determine whether the inhibition of kinin activity will alleviate CNS inflammation and whether kinin receptor antagonists are useful in pathological conditions of the CNS.
Walker
K
K
Sandoz Institute for Medical Research, London, U.K.
Perkins
M
M
Dray
A
A
D000595:Amino Acid Sequence; D000818:Animals; D001522:Behavior, Animal / Q000502:physiology; D001920:Bradykinin / Q000502:physiology; D002320:Cardiovascular Physiological Phenomena; D006801:Humans; D007249:Inflammation / Q000503:physiopathology; D007609:Kallidin / Q000502:physiology; D007705:Kinins / Q000502:physiology*; D008954:Models, Biological; D008969:Molecular Sequence Data; D009424:Nervous System Physiological Phenomena; D010146:Pain / Q000503:physiopathology; D051381:Rats; D018002:Receptors, Bradykinin / Q000145:classification / Q000187:drug effects / Q000502:physiology*; D014666:Vasomotor System / Q000187:drug effects / Q000502:physiology; D014947:Wounds and Injuries / Q000503:physiopathology
D007705:Kinins; D018002:Receptors, Bradykinin; C078647:kallidin receptor; D007609:Kallidin; D001920:Bradykinin